PPMD has recently learned that FibroGen has discontinued the LELANTOS-2 Open Label Extension. This news follows the August 2023 release of negative topline results of the Phase 3 LELANTOS-2 trial of pamrevlumab, FibroGen’s investigational anti-fibrotic monoclonal antibody, for ambulatory patients with Duchenne muscular dystrophy.
According to FibroGen, the company is currently awaiting 079 non-ambulatory Open Label Extension Study results (Mission Study), and intends to publish the data generated across LELANTOS-1 and -2.
PPMD is disappointed to learn FibroGen’s news. We have reached out to FibroGen for more information and will update the community as soon as we are able.
We are grateful to all the families who have participated in clinical trials with pamrevlumab, and to the FibroGen team for their work to advance therapy development in Duchenne. The discontinuation of a trial is always difficult for our community, but we remain hopeful that the data from this trial will inform other potential treatments and that these experiences will lead us to the day that we end Duchenne.